

Phar

# Clinical Pharmacokinetics

December 1993, Vol. 25, No. 6 (pp. 425-532)  
ISSN: 0312-5963

LEADING ARTICLE  
Once-Daily Aminoglycosides

REVIEW ARTICLES  
Lamotrigine Kinetics  
Interactions with Antimicrobials  
Antirheumatic Drugs in Pregnancy


ORIGINAL RESEARCH ARTICLES  
Time and Theophylline  
Theophylline Target Concentrations  
Salicylates in Malnourished Children



**adis**  
INTERNATIONAL

AUCKLAND • CHESTER • HONG KONG • MILAN • OSAKA • PHILADELPHIA • SYDNEY

IPR2015-00410  
Petitioners' Ex. 1031  
Page 1



# CNS Drugs

*The Clinical Review Journal of Drugs  
and Therapeutics in Psychiatry and Neurology*

**NEW FROM ADIS**  
Effective January 1994

**A MAJOR NEW JOURNAL**  
**CNS Drugs**  
**PUBLISHED MONTHLY**

RECEIVED

DEC 13 1993

UNIVERSITY LIBRARY

The Clinical Review Journal of Drugs and Therapeutics  
in Psychiatry and Neurology.

A comprehensive and readable review journal covering clinical  
aspects of psychiatric and neurological pharmacology.

Provides practical guides to the place in therapy and  
optimum use of newer and established agents.

Fully reviews and evaluates all aspects of new and  
emerging psychiatric and neurological drugs,  
becoming an invaluable reference source.

A timely relevant update and comprehensive reference.



1994 SUBSCRIPTION RATES: US\$540 (North America), SFr870 (Europe), US\$540 (Rest of World), ¥91,800 (Japan)  
TO SUBSCRIBE OR REQUEST FURTHER INFORMATION CONTACT YOUR LOCAL ADIS OFFICE

North & South America  
Ph: +1 215 741-5200  
Fax: +1 215 741-5251

Europe  
Ph: +44 244 328-328  
Fax: +44 244 320-787

Rest of World  
Ph: +852 511-0633  
Fax: +852 507-5554

Japan Agent (Technomics)  
Ph: +81 3 3666-2952  
Fax: +81 3 3666-2730

IPR2015-00410

Petitioners' Ex. 1031

Page 2

425-426 From the Editor

**LEADING ARTICLE**

427-432 Aminoglycoside Dosage Regimens: Is Once a Day Enough?  
*Hustinx WMN, Hoepelman IM*

**REVIEW ARTICLES**

DRUG DISPOSITION

433-443 Lamotrigine Clinical Pharmacokinetics  
*Rambeck B, Wolf P*

CLINICAL PHARMACOKINETICS AND DISEASE PROCESSES

444-449 Clinical Pharmacokinetics in the Treatment of Rheumatoid Arthritis  
in Pregnancy  
*Witter FR*

PHARMACOKINETIC DRUG INTERACTIONS

450-482 Pharmacokinetic Drug Interactions with Antimicrobial Agents  
*Gillum JG, Israel DS, Polk RE*

**ORIGINAL RESEARCH ARTICLES**

483-494 Disposition of Salicylic Acid in Malnourished Ethiopian Children  
after Single Oral Dose  
*Ashton M, Bolme P, Zerihun G, Holmberg K, Paalzow LK*

495-505 Theophylline Target Concentration in Severe Airways Obstruction –  
10 or 20 mg/L?  
*Holford N, Black P, Couch R, Kennedy J, Briant R*

506-515 Time and Theophylline Concentration Help Explain the Recovery  
of Peak Flow Following Acute Airways Obstruction  
*Holford N, Hashimoto Y, Sheiner LB*

516-518 **Cumulated Contents**

519-532 **Subject Index 1993**

*Clinical Pharmacokinetics* is indexed in 'Current Contents', 'Index Medicus' and 'Excerpta Medica'.

**Copyright:** The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center Inc., 21 Congress Street, Salem, Massachusetts 01970, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.



**International Editorial Board:**

*G. Alvan*, Stockholm, Sweden  
*D.L. Azarnoff*, South San Francisco, Calif., USA  
*D.J. Birkett*, Adelaide, S. Australia  
*A.M. Breckenridge*, Liverpool, England  
*D.D. Breimer*, Leiden, The Netherlands  
*J.M. Brogard*, Strasbourg, France  
*L. Dettli*, Basel, Switzerland  
*H. Echizen*, Tokyo, Japan  
*M. Eichelbaum*, Stuttgart, Federal Republic of Germany  
*J. Feely*, Dublin, Ireland  
*S. Garattini*, Milan, Italy  
*R. Gugler*, Karlsruhe, Federal Republic of Germany  
*N.H.G. Holford*, Auckland, New Zealand  
*U. Klotz*, Stuttgart, Federal Republic of Germany  
*J.-R. Laporte*, Barcelona, Spain  
*G. Levy*, Buffalo, N.Y., USA  
*D.G. Perrier*, Toronto, Ontario, Canada  
*E. Perucca*, Pavia, Italy  
*L.F. Prescott*, Edinburgh, Scotland  
*M.D. Rawlins*, Newcastle upon Tyne, England  
*M.M. Reidenberg*, New York, N.Y., USA  
*H. Shionoiri*, Yokohama, Japan  
*F. Sjöqvist*, Huddinge, Sweden  
*J.-P. Tillement*, Créteil, France  
*C.J. van Boxtel*, Amsterdam, The Netherlands  
*E.S. Vesell*, Hershey, Penn., USA  
*R.E. Vestal*, Boise, Idaho, USA  
*S. Vožeh*, Berne, Switzerland  
*J.T. Wilson*, Shreveport, La., USA  
*S.J. Yaffe*, Bethesda, Md., USA

**Editor:** Heather D. Langtry

**President and Publisher:** Graeme S. Avery  
**Group Editorial Director:** Rennie C. Heel  
**Executive Vice-President, International:** Neil R. Story  
**Executive Vice-President, Europe:** Steve I. Campbell  
**Executive Vice-President, USA:** Neil W. Matheson  
**Executive Vice-President, Japan:** Philip R. Smith  
**Consultant:** T. Harvey Oakes

**Editorial Manager, International Review Journals:** Paul Chrisp

**Senior Publication Editor:** David R. Britten  
**Senior Assistant Editor:** Paul C. Jinks  
**Assistant Editors:** Jodi Yeats, Teresa J. McIntyre  
**Editorial Secretaries:** Margot A. Callinan, Jan Cliff  
**Information Manager:** Sue Shoolbread  
**Proofreading:** Barbara Fleming  
**Graphic Artists:** Grant Shennan, Sue Boerkamp

**Aim and Scope:** Through a structured programme of review articles, the Journal aims to assist in the continuing development of clinical pharmacokinetics as a speciality area important for the improvement of drug therapy, and to further postgraduate education in clinical pharmacology and therapeutics. A particular emphasis is the aspect of pharmacokinetic-pharmacodynamic relationships (including both desired and unwanted effects). The scope of the Journal also includes pharmacokinetic properties of therapeutic drugs, therapeutic drug monitoring, influence of age or disease states on drug kinetics, pharmacokinetic optimisation of drug therapy, pharmacokinetic drug interactions, clinically relevant bioavailability issues and regulatory aspects of pharmacokinetics with practical implications.

Most manuscripts are subject to review by international experts. Referee comments are intended to improve the content and quality of the article, but may also influence acceptance for publication. Letters to the Editor are welcomed and may be considered for publication.

**Copyright:** © 1993 Adis International Ltd. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means electronic or mechanical including photocopying or recording or by any information storage and retrieval system without permission in writing from the publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure that it is accurate the authors the publisher and their servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors omissions or inaccuracies in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

**US Postmasters:** Send address changes to Adis International Inc., Suite F-10, 940 Town Center Drive, Langhorne, PA 19047, USA. Air freight and mailing in the US by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003, USA.

**Exclusive subscription agents in Japan:** Technomics Inc., CPO Box 882, Tokyo 100-91, Japan.

**Clinical Pharmacokinetics** (ISSN 0312-5963) is published monthly by Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. Annual subscription price: North & South America \$US540; Europe SwF870; Japan ¥91 800; rest of world \$US540. A subscription to *Clinical Pharmacokinetics* is accepted on the express condition that it will be used only internally, within an institution, company or national affiliate confined to one geographical location, and will not be copied and/or circulated outside these limits. An order for *Clinical Pharmacokinetics* constitutes an undertaking by the subscriber to comply with this condition. (Further subscription information is given in the *General Information* page printed at the back of each issue, as space allows.) Second class postage paid at Jamaica, NY 11431. Printed in Hong Kong by Caritas Printing Training Centre.

**Editorial Office and Editorial Inquiries:** Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

## Lamotrigine Clinical Pharmacokinetics

Bernhard Rambeck and Peter Wolf

Epilepsy-Centre Bethel and Department of Biochemistry, Gesellschaft für Epilepsieforschung,  
Bielefeld, Federal Republic of Germany

### Contents

433	Summary
434	1. Physicochemical Properties of Lamotrigine
434	2. Analytical Methods
434	2.1 High Performance Liquid Chromatography
435	2.2 Immunoassays
435	3. Pharmacokinetic Properties
435	3.1 Absorption
435	3.2 Distribution
436	3.3 Elimination
437	3.4 Autoinduction
437	4. Pharmacokinetics in Special Groups
437	4.1 Healthy Volunteers and Nonepileptic Patients
438	4.2 Adults with Epilepsy
438	4.3 Children with Epilepsy
438	5. Drug Interactions
438	5.1 Effect of Other Drugs on Lamotrigine
439	5.2 Effect of Lamotrigine on Other Drugs
439	5.3 Pharmacodynamic Interactions
440	6. Drug Monitoring
440	7. Safety and Adverse Events
441	8. Therapeutic Implications

### Summary

Lamotrigine is a new antiepileptic agent chemically unrelated to any established drugs in use. The drug can be estimated in biological fluids by high performance liquid chromatography and immunoassays. It is rapidly absorbed, reaching peak concentrations within about 3 hours postdose. The bioavailability of the oral formulation is about 98%. The area under the plasma concentration-time curve indicates dose-linear pharmacokinetics. The degree of plasma protein binding is 56%. Saliva concentrations are 46% of the plasma concentration. The concentration of lamotrigine in the brain is similar to the total concentration in the plasma.

Lamotrigine exhibits first-order linear kinetics during long term administration. 43 to 87% of a dose is recovered in the urine, predominantly as glucuronide metabolites. Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours. Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.